Biotech company CSL has posted a six per cent drop in full-year net profit to $US2.26 billion ($A3.22 billion) after supplies of its key blood plasma products were disrupted.
On a statutory basis, profit for the year to June 30 was down five per cent, on a constant currency basis.
The vaccines and blood products supplier still managed to lift revenue by two per cent to $US10.56 billion ($A15.03 billion).
